Effectiveness of Echinochrome on HFD-Induced Hyperlipidemia in Rats

doi:10.1007/s13659-019-00221-4

Natural Products and Bioprospecting ›› 2019, Vol. 9 ›› Issue (5): 337-344.DOI: 10.1007/s13659-019-00221-4

• ORIGINAL ARTICLES • Previous Articles Next Articles

Effectiveness of Echinochrome on HFD-Induced Hyperlipidemia in Rats

Sohair R. Fahmy¹, Nashwah Ismail Zaki², Shaimaa Zakaria Eid¹, Ayman Saber Mohamed¹, Sarah S. Hassanein¹

1 Zoology Department, Faculty of Science, Cairo University, Giza 12613, Egypt;
2 Physiology Department, National Organization for Drug Control and Research, Cairo, Egypt

Received:2019-08-21 Revised:2019-10-06 Online:2019-10-30 Published:2019-10-24
Contact: Ayman Saber Mohamed, Sohair R. Fahmy, Nashwah Ismail Zaki, Shaimaa Zakaria Eid, Sarah S. Hassanein

Effectiveness of Echinochrome on HFD-Induced Hyperlipidemia in Rats

Sohair R. Fahmy¹, Nashwah Ismail Zaki², Shaimaa Zakaria Eid¹, Ayman Saber Mohamed¹, Sarah S. Hassanein¹

1 Zoology Department, Faculty of Science, Cairo University, Giza 12613, Egypt;
2 Physiology Department, National Organization for Drug Control and Research, Cairo, Egypt

通讯作者: Ayman Saber Mohamed, Sohair R. Fahmy, Nashwah Ismail Zaki, Shaimaa Zakaria Eid, Sarah S. Hassanein

Abstract

Abstract: Obesity has been identified with an expanded danger of a progression of illnesses that include different organ-frameworks of the body. In the present examination, we evaluated the hypolipidemic properties of Echinochrome (Ech) pigment in a highfat diet (HFD) induced hyperlipidemia in rats. After the hyperlipidemic model was set up, rats were haphazardly separated into five groups as follows:normal control group, HFD group, Atorvastatin (ATOR) group (80 mg/kg), Ech group (1 mg/kg) and combined group ATOR + Ech. The outcomes demonstrated that Ech improves lipid profile, liver functions, kidney functions and antioxidant markers of obese rats. The findings of the present investigation indicated that the Ech possesses hypolipidemic potential in obese rats.

Key words: High-fat diet, Atorvastatin, Echinochrome, Obesity, Oxidative stress

摘要： Obesity has been identified with an expanded danger of a progression of illnesses that include different organ-frameworks of the body. In the present examination, we evaluated the hypolipidemic properties of Echinochrome (Ech) pigment in a highfat diet (HFD) induced hyperlipidemia in rats. After the hyperlipidemic model was set up, rats were haphazardly separated into five groups as follows:normal control group, HFD group, Atorvastatin (ATOR) group (80 mg/kg), Ech group (1 mg/kg) and combined group ATOR + Ech. The outcomes demonstrated that Ech improves lipid profile, liver functions, kidney functions and antioxidant markers of obese rats. The findings of the present investigation indicated that the Ech possesses hypolipidemic potential in obese rats.

关键词: High-fat diet, Atorvastatin, Echinochrome, Obesity, Oxidative stress

Sohair R. Fahmy, Nashwah Ismail Zaki, Shaimaa Zakaria Eid, Ayman Saber Mohamed, Sarah S. Hassanein. Effectiveness of Echinochrome on HFD-Induced Hyperlipidemia in Rats[J]. Natural Products and Bioprospecting, 2019, 9(5): 337-344.

Sohair R. Fahmy, Nashwah Ismail Zaki, Shaimaa Zakaria Eid, Ayman Saber Mohamed, Sarah S. Hassanein. Effectiveness of Echinochrome on HFD-Induced Hyperlipidemia in Rats[J]. 应用天然产物, 2019, 9(5): 337-344.

References

1. W. Gao, H.W. He, Z.M. Wang, H. Zhao, X.Q. Lian, Y.S. Wang, J. Zhu, J.J. Yan, D.G. Zhang, Z.J. Yang, L.S. Wang, Lipids Health Dis. 11, 55-59 (2012)
2. S.S. Lim, T. Vos, A.D. Flaxman, Lancet 380, 2224-2260 (2010)
3. S. Saravanan, L. Pari, Eur. J. Pharmacol. 76, 279-287 (2015)
4. Y. Eguchi, H. Hyogo, M. Ono, T. Mizuta, N. Ono, K. Fujimoto, K. Chayama, T. Saibara, JSG-NAFLD J. Gastroenterol. 47, 586-595 (2012)
5. A.J. Sanyal, C. Campbell-Sargent, F. Mirshahi, W.B. Rizzo, M.J. Contos, R.K. Sterling, V.A. Luketic, M.L. Shiffman, J.N. Clore, Gastroenterology 120, 1183-1192 (2001)
6. R.L. Yang, Y.H. Shi, G. Hao, W. Li, G.W. Le, J. Clin. Biochem. Nutr. 43, 154-158 (2008)
7. B.A. Golomb, M.A. Evans, Am. J. Cardiovasc. Drugs. 8, 373-418 (2008)
8. P. Kaufmann, M. Török, A. Zahno, K.M. Waldhauser, K. Brech, S. Krähenbühl, Cell Mol. Life Sci. 63, 2415-2425 (2006)
9. S. Kianbakht, F. Nabati, B. Abasi, Int. J. Mol. Cell Med. 5(3), 141-148 (2016)
10. G.M. Markus, H.K. Richard, B.B. Eduard, S.-F. Verónica, M. Katia, L. Lakshmanan, H. Hans, B. Fabio, D. Annette, CMAJ 181, E11-E18 (2009)
11. S.R. Fahmy, A.S. Mohamed, Int. J. Clin. Exp. Pathol. 8, 1649-1657 (2015)
12. A.V. Lebedev, M.V. Ivanova, D.O. Levitsky, Life Sci. 76, 863-875 (2005)
13. L.V. Boguslavskaya, N.G. Khrapova, O.B. Maksimov, Bull. Acad. Sci. USSR Div. Chem. Sci. 34, 1345-1350 (1985)
14. S.H. Jeong, H.K. Kim, I.S. Song, S.J. Noh, J. Marquez, K.S. Ko, B.D. Rhee, N. Kim, N.P. Mishchenko, S.A. Fedoreyev, V.A. Stonik, J. Han, Mar. Drugs. 12, 4602-4615 (2014)
15. A.M. Soliman, A.S. Mohamed, M.A.S. Marie, Austin J. Endocrinol Diabetes 3, 1045 (2016)
16. V. Welch-White, N. Dawkin, T. Graham, R. Pace, Lipids Health Dis. 12, 2-9 (2013)
17. A.V. Lebedev, L.V. Boguslavskaia, D.O. Levitskii, O.B. Maksimov, Biokhimiia. 53, 598-603 (1988)
18. S. Vazquez-Perez, P. Aragoncillo, N. de Las Heras, J. NavarroCid, E. Cediel, D. Sanz-Rosa, L. M. Ruilope, C. Diaz, G. Hernandez, V. Lahera and V. Cachofeiro. Nephrol. Dial Transpl. 16, 40-44 (2001).
19. M. Hattori, D.J. Nikotic-Paterson, K. Miyazaki, N.M. Isbel, H.Y. Lan, R.C. Atkin, H. Kawaguchi, K. Ito, Kidney Int. Suppl. 71, S47-S50 (1999)
20. C. Yang, C. Lium, Q. Zhoum, Y.C. Xiem, X. Qiu, X. Feng, Indian J. Pharm. Sci. 77, 103-107 (2015)
21. B.A. Bhatt, J.J. Dube, N. Dedousis, J.A. Reider, R.M. O'Doherty, Am. J. Physiol-Reg. Integ. Comp. Physiol. 290, R233-R240 (2006)
22. L. Marcoff, P.D. Thompson, J. Am. Coll. Cardiol. 49, 2231-2237 (2007)
23. F.W. Fraunfelder, A.B. Richards, Ophthalmology 115, 2282-2285 (2008)
24. P. Kapoor, A.K. Kapoor, JIACM. 14, 37-45 (2013)
25. S.A. Noeman, H.E. Hamooda, A.A. Baalash, Diabetol. Metab. Syndr. 3, 17 (2011)
26. A. Guilherme, J.V. Virbasius, V. Puri, M.P. Czech, Nat. Rev. Mol. Cell Biol. 9, 367-377 (2008)
27. A.E. Butler, J. Janson, S. Bonner-Weir, R. Ritzel, R.A. Rizza, P.C. Butler, Diabetes 52, 102-110 (2003)
28. R. Amarowicz, J. Synowiecki, F. Shahidi, Food Chem. 51, 227-229 (1994)
29. R. Kuwahara, H. Hatatea, T. Yukia, H. Murata, R. Tanakac, Y. Hamad, L.W.T. Food Sci. Technol. 42, 1296-1300 (2009)
30. M.J. Reed, K. Meszaros, L.J. Entes, M.D. Claypoo, J.G. Pinkett, T.M. Gadbois, G.M. Reaven, Metabolism. 49, 390-1394 (2000)
31. G. Rajyalakshmi, A. Reddy, V.V. Rajesham, Int. J. Pharm. 6, 2 (2009)
32. A. Lennikov, N. Kitaichi, K. Noda, K. Mizuuchi, R. Ando, Z. Dong, J. Fukuhara, S. Kinoshita, K. Namba, S. Ohno, S. Ishida, Mol. Vis. 20, 171-177 (2014)
33. S.S. Reitman, A. Frankel, Am. J. Clin. Pathol. 28, 56-63 (1957)
34. A. Belfield, D.M. Goldberg, Arch. Dis. Child. 46, 842-486 (1971)
35. N. W. Tietz, C. A. Burtis and E. R. Ashwood. Tietz Textbook of Clinical Chemistry, pp. 122-133. Saunders, Philadelphia (1994)
36. N. W. Tietz, P. Finley and E. Pruden. Clinical Guide to Laboratory Tests Saunders, pp. 232-233. Saunders, Philadelphia (1990)
37. N. Zollner, K. Kirsch, Z. Ges. Exp. Med. 135, 545-561 (1962)
38. E.A. Stein, G. Myers, in Tietz Textbook of Clinical Chemistry, ed. by C.A. Burtis, R.E. Ashwood (WB Saunders Company, Philadelphia, 1994), pp. 1002-1993
39. W. Richmond, Clin. Chem. 19, 1350-1356 (1973)
40. H. Wieland, D. Seidel, J. Lipid Res. 24, 904-909 (1983)
41. M.F. Lopes-Virella, P. Stone, S. Ellis, J.A. Colwell, Clin. Chem. 23, 882-884 (1977)
42. J. Schirmeister, Dtsch. Med. Wschr. 89, 1940 (1964)
43. J.K. Fawcett, J.E. Soctt, J. Clin. Pathol. 13, 156-159 (1960)
44. D. Barham, P. Trinder, Analyst. 151, 142-145 (1972)
45. A. Renze, P. Margaret, JIFCC. 1, 130-139 (1989)
46. H. Ohkawa, N. Ohishi, K. Yagi, Anal. Biochem. 95, 351-358 (1979)
47. E. Beutler, O. Duron, M.B. Kelly, J. Lab. Clin. Med. 61, 882-888 (1963)
48. W.H. Habig, M.J. Pabst, W.B. Jakoby, J. Biol. Chem. 249, 7130-7139 (1974)
49. H. Aebi, Methods Enzymol. 105, 121-126 (1984)

[1]	Hai-Hui Guo, Lei Wu, Dan Mi, Xing-Yu Zhang, Fu-Mei He, Ting Lei, Fu-Sheng Wang. Polysaccharide fraction from Triplostegia glandulifera Wall and its renoprotective effect in streptozotocin-induced diabetic mice by attenuating oxidative stress [J]. Natural Products and Bioprospecting, 2024, 14(5): 47-47.
[2]	Lingli Ding, Zhao Gao, Siluo Wu, Chen Chen, Yamei Liu, Min Wang, Yage Zhang, Ling Li, Hong Zou, Guoping Zhao, Shengnan Qin, Liangliang Xu. Ginsenoside compound-K attenuates OVX-induced osteoporosis via the suppression of RANKL-induced osteoclastogenesis and oxidative stress [J]. Natural Products and Bioprospecting, 2023, 13(6): 49-49.
[3]	Ding-kang Chen, Hui-yan Shao, Liu Yang, Jiang-miao Hu. The bibenzyl derivatives of Dendrobium officinale prevent UV-B irradiation induced photoaging via SIRT3 [J]. Natural Products and Bioprospecting, 2022, 12(1): 1-11.
[4]	Soad Z. El-Emam. Sesamol Alleviates the Cytotoxic Effect of Cyclophosphamide on Normal Human Lung WI-38 Cells via Suppressing RAGE/NF-κB/Autophagy Signaling [J]. Natural Products and Bioprospecting, 2021, 11(3): 333-344.
[5]	Mohaddese Mahboubi. Caraway as Important Medicinal Plants in Management of Diseases [J]. Natural Products and Bioprospecting, 2019, 9(1): 1-12.
[6]	Kun Wei, Gang-Qiang Wang, Xue Bai, Yan-Fen Niu, He-Ping Chen, Chun-Nan Wen, Zheng-Hui Li, Ze-Jun Dong, Zhi-Li Zuo, Wen-Yong Xiong, Ji-Kai Liu. Structure-Based Optimization and Biological Evaluation of Pancreatic Lipase Inhibitors as Novel Potential Antiobesity Agents [J]. Natural Products and Bioprospecting, 2015, 5(3): 129-157.
[7]	Simon CICHELLO, Pingsheng LIU, Markendya JOIS. The anti-obesity effects of EGCG in relation to oxidative stress and air-pollution in China [J]. Natural Products and Bioprospecting, 2013, 3(6): 256-266.

Effectiveness of Echinochrome on HFD-Induced Hyperlipidemia in Rats

Effectiveness of Echinochrome on HFD-Induced Hyperlipidemia in Rats

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 7

Recommended Articles

Metrics

Comments